Skip to Main Content

60

Views

2

CrossRef citations to date

0

Altmetric

Original Research

Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy

Vybhav JettyDepartment of Internal Medicine, Cholesterol Center, Jewish Hospital of Cincinnati, Cincinnati, OH, USACorrespondence[email protected]

,

Charles J GlueckDepartment of Internal Medicine, Cholesterol Center, Jewish Hospital of Cincinnati, Cincinnati, OH, USA

,

Kevin LeeDepartment of Internal Medicine, Cholesterol Center, Jewish Hospital of Cincinnati, Cincinnati, OH, USA

,

Naila GoldenbergDepartment of Internal Medicine, Cholesterol Center, Jewish Hospital of Cincinnati, Cincinnati, OH, USA

,

Marloe PrinceDepartment of Internal Medicine, Cholesterol Center, Jewish Hospital of Cincinnati, Cincinnati, OH, USA

,

Ashwin KumarDepartment of Internal Medicine, Cholesterol Center, Jewish Hospital of Cincinnati, Cincinnati, OH, USA

,

Michael GoldenbergDepartment of Internal Medicine, Cholesterol Center, Jewish Hospital of Cincinnati, Cincinnati, OH, USA

,

Ishan AnandDepartment of Internal Medicine, Cholesterol Center, Jewish Hospital of Cincinnati, Cincinnati, OH, USA

&

Ping WangDepartment of Internal Medicine, Cholesterol Center, Jewish Hospital of Cincinnati, Cincinnati, OH, USA